厄贝沙坦氢氯噻嗪对高血压病患者血清C-反应蛋白浓度影响

目的：探讨厄贝沙坦氢氯噻嗪对高血压患者血清C-反应蛋白（CRP）浓度影响。方法：选择高血压患者50例，于用药前测定其CRP浓度；在厄贝沙坦氢氯噻嗪口服6周后再测定其血清CRP浓度。根据治疗后血压达标与否，分为血压达标组（28例）与非达标组（22例），比较各组患者治疗前后血清CRP的变化。结果：与治疗前比较，治疗后血压达标组和非达标组患者血清CRP浓度均明显降低[（6．62±3．73）mg／L比（4．63±2．01）mg／L，（6．51±3．15）mg／L比（4．85±2．25）mg／L，P均〈0．05]；血压达标组的血清CRP浓度低于非达标组的，但未达显著水平，P均〉0．05。结论：高血压患者服用厄贝沙坦氢氯噻嗪后血清C-反应蛋白浓度下降，提示厄贝沙坦可降低高血压患者的炎症反应。

Influence of irbesartan and hydrochlorothiazide on serum concentration of C reactive protein in patients with hypertension

Objective： To explore influence of irbesartan and hydrochlorothiazide on serum concentration of C reac-tive protein （CRP） in patients with hypertension. Methods： A total of 50 patients with hypertension were enrolled and their serum CRP concentrations were measured before medication; serum CRP concentration was measured af- ter six-week medication of irbesartan and hydrochlorothiazide. According to blood pressure reached standard or not after treatment, the patients were divided into blood pressure standard-reaching group （n = 28） and not standard- reaching group （n = 22）, change of serum CRP concentration before and after treatment was compared between two groups. Results： Compared with before treatment, there was significant decrease in serum concentration of CRP [ （6. 62±3.73） mg/Lvs. （4.63±2.01） mg/L, （6.51±3.15） mg/Lvs. （4. 85±2.25） mg/L, P〈0.05 both] in blood pressure standard-reaching group and not standard-reaching group respectively; The serum CRP concentration of standard-reaching group was lower than that of not standard-reaching group, but did not reach significant level. Conclusion： Irbesartan and hydrochlorothiazide may decrease serum concentration of C reactive protein, suggests that Irbesartan may decrease inflammatory reaction in patients with hypertension.